RecruitingNCT03423680

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Depression in bipolarity

This recruiting study focuses on bipolarity and currently lists sites or participation links in South Korea.

BipolarityOtherFrom 19 Years to 70 Years

In plain English

Key information made simple

This study exists to compare options and see whether the medication Abilify offers something meaningfully different. Researchers are trying to understand how people respond to the medication Abilify in practice and what may need to be adjusted. For people living with Bipolarity, the gap between what sounds good on paper and what works in daily life is often important. If the findings are useful, they could help future care become more targeted, practical, and easier to trust. Taking part helps build the evidence that can improve understanding and care for others over time.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Seounl National University Hospital in Seoul. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and meeting the main study requirements, while common reasons not to take part include safety concerns that need urgent care first and other clinical factors that could make participation unreliable or unsafe. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Interested?

Check my eligibility

Study reference: NCT03423680. Your email is the only field you need to provide here.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in South Korea.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com